Aims: To characterize the glycaemic efficacy and safety of initiation of the dipeptidyl peptidase-4 inhibitor sitagliptin during metformin dose escalation in people with type 2 diabetes (T2D) not at glycated haemoglobin (HbA1c) goal on a sub-maximal dose of metformin. 20 was higher in the sitagliptin group than in the placebo group in the overall population (relative risk 1.7, P = 0.002) and in those with a baseline HbA1c ≥69 mmol/mol (≥8.5%) (relative risk 2.4, P = 0.026). There were no notable differences between groups with regard to adverse events overall, hypoglycaemia events, changes in body weight or other safety variables.
is considered a typical treatment target for most patients with T2D, and anti-hyperglycaemic agents (AHAs) are usually initiated and intensified in a stepped-care fashion, based on glycaemic response relative to this goal. Because of its favourable efficacy, safety and cost, metformin is the first-line AHA for most patients with T2D. It is typically initiated at 500-1000 mg/d, with dose escalations occurring as required, based on HbA1c re-assessments, up to doses of 2000 to 2500 mg/d. 2 If dose uptitration of metformin monotherapy does not result in HbA1c goal attainment, one or more other AHAs are added.
This stepped-care approach can substantially delay HbA1c goal attainment in patients who ultimately require two or more AHAs for optimal glycaemic control. A recent analysis of observational data in the United Kingdom indicated that only 25% of patients with T2D
with HbA1c ≥53 mmol/mol (≥7.0%) received treatment intensification within 12 months. 3 Further, the likelihood of attaining glycaemic control was significantly lower for patients with delayed intensification.
More aggressive approaches may therefore be considered in patients as monotherapy and in combination with other AHAs. 4 When used in combination with metformin, sitagliptin provides clinically meaningful improvement in glycaemic control and is generally well tolerated, without body weight gain or increased incidence of hypoglycaemia [5] [6] [7] [8] ; however, these studies have evaluated sitagliptin as add-on therapy to patients on stable doses of metformin, or as initial co-administration with metformin.
The present study, CompoSIT-M (Comparison of SITagliptin vs. placebo during Metformin uptitration), was designed to characterize, in participants with T2D who were not at HbA1c goal on a sub-maximal dose of metformin, the glycaemic efficacy and safety of metformin dose uptitration, with and without simultaneous initiation of sitagliptin.
2 | METHODS 
| Study population

| Study design
The study was a multinational, double-blind, randomized, placebocontrolled clinical trial, and included the following: a ≤2-week screening period; a period after completion of screening to allow glycaemic stabilization on metformin IR 1000 mg/d (500 mg twice daily) which was ≥10, ≥8 or ≥6 weeks for those on no AHA at screening, those transitioning to metformin IR from a non-metformin AHA, and those already taking 1000 mg/d metformin (IR or XR) at screening, respectively; a 2-week single-blind placebo run-in period; a 20-week doubleblind treatment period; a post-treatment telephone call~2 weeks after the final dose of study medication ( Figure 1 ).
After the placebo run-in period, participants were randomized centrally, using an interactive voice response system, in a 1:1 ratio to sitagliptin or matching placebo. Randomization was stratified based on the participants' use of AHAs at screening (not on AHA; on permissible non-metformin AHA; on metformin IR or metformin XR 1000 mg/d).
All participants were to increase the dose of IR to 1500 mg/d (1000 mg morning, 500 mg afternoon) on the day of randomization and to 2000 mg/d (1000 mg twice daily) on day 8. Any participant unable to tolerate metformin IR 1000 mg twice daily by week 6 was to continue on the highest dose of metformin IR they had tolerated for the remainder of the study. Clinic visits occurred at screening, prior to the metformin IR stabilization period (8-12 weeks pre-randomization), prior to the placebo run-in (2 weeks pre-randomization), randomization (week 0) and weeks 6, 14 and 20 post-randomization. Telephone contacts occurred 9 days after randomization to confirm appropriate uptitration of metformin IR, and 14 days after the last dose of study medication.
During the 20-week double-blind study period, participants with fasting plasma glucose (FPG) measurements consistently greater than specified thresholds (FPG >15 mmol/L after randomization and through week 6; FPG >13.3 mmol/L after week 6) were to receive glycaemic rescue therapy while also continuing double-blind study medication. The specific rescue therapy was determined by the investigator but could not include a DPP-4 inhibitor or an increase in the metformin dose.
The study (MK-0431-848; NCT02791490, EudraCT: 2015-004224-59) was conducted in accordance with the principles of Good Clinical Practice and approved by the appropriate institutional review boards and regulatory agencies.
| Study evaluations
All objectives of this study were to compare the effects of metformin 
| Efficacy assessments
Measurements of HbA1c and FPG were collected at the screening visit, prior to the placebo run-in, at baseline (pre-dose on the day of randomization) and at 6, 14 and 20 weeks after randomization.
| Safety assessments
Adverse events (AEs) were collected at all study visits and during telephone contacts. Protocol-specified safety assessments included 3 | RESULTS
| Patient disposition and characteristics
The study was conducted at 68 sites in eight countries (a list of investigators can be found in Table S1 ) and was initiated on 21 June 2016 and completed on 1 February 2018. A total of 1100 patients were screened and 458 were randomized.
Baseline demographics and disease characteristics were generally balanced between the treatment groups ( the study were similar in the two groups, with withdrawal by participant choice being the most common ( Figure S1 ). Reasons for withdrawal from study medication were also similar between groups, but more varied ( Figure S1 ). Over 97% of all study participants increased their metformin dose from 1000 mg/d (500 mg twice daily) at randomization to 2000 mg/d (1000 mg twice daily) by 15 days post-randomization as required per protocol, and 94.1% (92.1% on sitagliptin and 96.1% on placebo) were taking 1000 mg twice daily metformin at study completion. 
| Efficacy
| Safety and tolerability
The incidences of AEs, including those assessed by the investigator as being related to study medication, were similar in the two treatment groups (Table 3) . No deaths were reported during the study. The incidence of serious AEs (SAEs) was low and similar in the two groups and no drug-related SAEs were reported. The incidences of specific AEs by system organ class for which ≥4 AEs were reported in at least one treatment group were also generally similar in the two groups (Table S2 ). The only specific AEs for which the 95% CI for the between-group difference in incidence excluded zero were dyspepsia and tonsillitis, which were both reported at higher incidences in the placebo group. There were no notable changes from baseline or between-group differences in blood pressure, heart rate, body weight, routine chemistry or lipid analyses. The observed incidence of documented symptomatic hypoglycaemia events was low in both groups and the 95% CI for the between-group difference in incidence included zero (difference 1.7 [95% CI −0.8, 4.8]; Table 3 ). No severe hypoglycaemia events were reported in the study. 4% of participants at HbA1c of <7.0%. 12 The higher percentage of participants at HbA1c goal reported in these studies compared with the present study may be largely attributable to the lower baseline HbA1c levels in the earlier studies (7.3% and 7.97%) than in the present study (8.7%). However, the similar rate of HbA1c goal attainment in these two prior studies is surprising given their substantial baseline HbA1c differences and may reflect differences in what is often observed as a "trial effect". Collectively, these two studies and the present study illustrate that the potential for metformin dose uptitration to result in HbA1c goal attainment is substantially determined by proximity to the HbA1c target at the time of dose uptitration. Future analyses of data from the present study may better Abbreviations: AHA, anti-hyperglycaemic agent; BMI, body mass index; FPG, fasting plasma glucose; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; IR, immediate release; T2D, type 2 diabetes; XR, extended release. Values are mean ± SD, unless otherwise indicated. a To convert to mg/dL multiply mmol/L value by 18. b One participant, enrolled in error, was on both metformin and a sulphonylurea at screening and is included in the "On metformin IR or metformin XR 1000 mg/d" row.
delineate the relationship between baseline HbA1c and the likelihood of glycaemic goal attainment with metformin dose uptitration alone to clarify the patient population most appropriate for initiation of a second AHA prior to metformin dose uptitration.
In the context of the present study, an additional patient management consideration is clinical or therapeutic inertia, i.e. the failure to initiate or intensify therapy when indicated. This is a common, longrecognized factor limiting HbA1c goal attainment in many patients with T2D, attributed to multiple clinician-related factors including lack of treatment target awareness and concerns regarding patient adherence and potential for medication side effects. [13] [14] [15] [16] [17] [18] Multiple studies, including those in patients on metformin monotherapy, have demonstrated median delays in excess of 1 year to appropriate treatment intensification for patients with T2D not at HbA1c goal. 19 Given its Strengths of the present study include the randomized, doubleblind design, the high completion rate and the high degree of adherence to protocol-mandated metformin uptitration. Additionally, the study used broad enrolment criteria, resulting in a study population generally representative of the T2D population receiving metformin, although there was minimal enrolment of black or Asian participants. Overall Population FIGURE 2 Glycaemic efficacy endpoints. Open circles = metformin uptitration + placebo; filled circles = metformin uptitration + sitagliptin. Data in all figures were calculated using the longitudinal data analysis model as described in methods. A, Least squares (LS) mean ± SE change from baseline glycated haemoglobin (HbA1c); B, Percentage of participants at HbA1c <7.0% at week 20 and percentage of participants with baseline HbA1c ≥8.5% at HbA1c <7.0% at week 20. C, LS mean ± SE change from baseline fasting plasma glucose (FPG). RR, relative risk 
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